Rhabdomyosarcoma

Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low‐risk and intermediate‐risk disease but not for patients with a metastatic disease. We reviewed and contrasted the...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2021-05, Vol.68 (S2), p.e28254-n/a
Main Authors: Yechieli, Raphael L., Mandeville, Henry C., Hiniker, Susan M., Bernier‐Chastagner, Valerie, McGovern, Susan, Scarzello, Giovanni, Wolden, Suzanne, Cameron, Alison, Breneman, John, Fajardo, Raquel Davila, Donaldson, Sarah S.
Format: Article
Language:English
Subjects:
Chemotherapy
Clinical trials
Metastases
Oncology
Patients
Pediatrics
Radiation therapy
Rhabdomyosarcoma
Surgery
surgery radiation oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low‐risk and intermediate‐risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging‐based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.28254